PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-37.55%
Negative net income growth while GNPX stands at 13.28%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
14.84%
Some D&A expansion while GNPX is negative at -4.46%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
0.81%
Less SBC growth vs. GNPX's 16.07%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
106.29%
Slight usage while GNPX is negative at -279.51%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.80%
Some yoy usage while GNPX is negative at -10.66%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
No Data
No Data available this quarter, please select a different quarter.
9.51%
Some CFO growth while GNPX is negative at -16.94%. John Neff would note a short-term liquidity lead over the competitor.
38.16%
Some CapEx rise while GNPX is negative at -1.90%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.16%
We have mild expansions while GNPX is negative at -1.90%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
1171.17%
We slightly raise equity while GNPX is negative at -100.00%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.